Ironwood Pharmaceuticals | IRWD - Debt


Ironwood Pharmaceuticals reported $583.99M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Almirall EUR 342.86M 61.94M Dec/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
Ardelyx USD 207.61M 968K Sep/2025
Astellas Pharma JPY 831.43B 83.94B Mar/2025
AstraZeneca USD 32.63B 207M Sep/2025
Charles River Laboratories USD 2.63B 157.4M Sep/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
MacroGenics USD 37.01M 238K Sep/2025
Moderna USD 734M 7M Sep/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 372.19M 4.53M Dec/2025
PTC Therapeutics USD 2.71B 2.42B Dec/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Takeda JPY 4.85T 208B Dec/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024